



FORM 7
MONTHLY PROGRESS REPORT

Name of CNSX Issuer: **Global Wellness Strategies Inc.** (the "Issuer" of the ("Company")).

Trading Symbol: **GWS**

Number of Outstanding Listed Securities: **23,626,906**

Number of Shares Reserved for Issuance: **478,750**

Date: **December 06, 2021**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.
The Company has appointed Associate Professor Michael Keane as a Key Opinion Leader to oversee the Shanti Therapeutics clinical trials.

CEO, Meris Kott, spoke at the first ever Lift&Co Psychedelic Business Summit, Canada's No. 1 Cannabis Conference and Trade Show, at the Metro Toronto Convention Centre, held on November 18-21, 2021.

Wholly-owned subsidiary, Shanti Therapeutics, has a filed provisional patent application for the treatment of pain with MDMA. A Phase 2a clinical trial is scheduled to commence recruitment in Q1 2022. Shanti has submitted an application to Swinburne University to the University Institutional Review Board for a Human Rights Ethics Committee review.

2. Provide a general overview and discussion of the activities of management.
The Company continues to actively seek and pursue opportunities within the fast-growing market for wellness consumer products. The corporate focus remains on global wellness, hemp and CBD, healthcare-related target companies.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
Not applicable.
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
Not Applicable

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
Not Applicable
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
Not Applicable
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
Not Applicable.
8. Describe the acquisition of new customers or loss of customers.
Not Applicable
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
Shanti Therapeutics has a filed provisional patent application for the treatment of pain with MDMA and upon completion of the initial clinical trials, the provisional patent will be upgraded to a global PCT patent with USPTO coverage.
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
Not Applicable
11. Report on any labour disputes and resolutions of those disputes if applicable.
Not Applicable
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
Not Applicable
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
Not applicable.

14. Provide details of any securities issued and options or warrants granted.
Not applicable.
15. Provide details of any loans to or by Related Persons.
Not Applicable.
16. Provide details of any changes in directors, officers or committee members.
The Company has appointed Associate Professor Michael Keane as Key Opinion Leader to guide the study methodology and choice of efficacy endpoints for the Shanti trials.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion and Analysis (the "MD&A") under the headings "Financial Instruments and Risk Management" and "Risks and Uncertainties". The MD&A is available on the Issuer's SEDAR profile at www.sedar.com and on the Issuer's disclosure hall with the CSE at www.thecse.com.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 06, 2021.

Meris Kott
Name of Director or Senior Officer

"Meris Kott"
Signature
CEO
Official Capacity

Issuer Details Name of Issuer Global Wellness Strategies Inc.		For Month End November 2021	Date of Report YY/MM/D 21/12/06
Issuer Address #1100-1111 Melville Street			
City/Province/Postal Code Vancouver BC V6E3V6	Issuer Fax No.	Issuer Telephone No. 604.484.0355	
Contact Name Meris Kott	Contact Position CEO - Director	Contact Telephone No. 604.484.0355	
Contact Email Address info@globalwellnessstrategies.com	Web Site Address www.globalwellnessstrategies.com		